IL145051A0 - 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists - Google Patents

4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Info

Publication number
IL145051A0
IL145051A0 IL14505100A IL14505100A IL145051A0 IL 145051 A0 IL145051 A0 IL 145051A0 IL 14505100 A IL14505100 A IL 14505100A IL 14505100 A IL14505100 A IL 14505100A IL 145051 A0 IL145051 A0 IL 145051A0
Authority
IL
Israel
Prior art keywords
methoxy
heterocyclysulfonamidyl
phenoxy
pyridyl
preparation
Prior art date
Application number
IL14505100A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL145051A0 publication Critical patent/IL145051A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL14505100A 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists IL145051A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03
PCT/EP2000/001660 WO2000052007A1 (fr) 1999-03-03 2000-02-28 Derives 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine, preparations et utilisations comme antagonistes du recepteur d'endotheline

Publications (1)

Publication Number Publication Date
IL145051A0 true IL145051A0 (en) 2002-06-30

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14505100A IL145051A0 (en) 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Country Status (30)

Country Link
US (2) US6417360B1 (fr)
EP (1) EP1185525B1 (fr)
JP (1) JP3488203B2 (fr)
KR (1) KR100478798B1 (fr)
CN (1) CN1342158B (fr)
AR (1) AR044720A1 (fr)
AT (1) ATE353325T1 (fr)
AU (1) AU756738B2 (fr)
BR (1) BR0008717A (fr)
CA (1) CA2364906C (fr)
CY (1) CY1108002T1 (fr)
CZ (1) CZ300324B6 (fr)
DE (1) DE60033280T2 (fr)
DK (1) DK1185525T3 (fr)
ES (1) ES2280198T3 (fr)
HK (1) HK1044943B (fr)
HR (1) HRP20010630B1 (fr)
HU (1) HUP0200080A3 (fr)
ID (1) ID30484A (fr)
IL (1) IL145051A0 (fr)
MA (1) MA26776A1 (fr)
NO (1) NO320809B1 (fr)
NZ (1) NZ513671A (fr)
PL (1) PL198815B1 (fr)
PT (1) PT1185525E (fr)
RS (1) RS50109B (fr)
RU (1) RU2201928C1 (fr)
TR (1) TR200102562T2 (fr)
WO (1) WO2000052007A1 (fr)
ZA (1) ZA200107157B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (fr) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines pour le traitement des néphropaties diabétiques
EP1595880A1 (fr) * 2004-05-13 2005-11-16 Speedel Pharma AG Formes crystallines d'un pyridinylsulphonamide et leur utilisation comme antagonistes du récepteur de l'endothéline
BRPI0615794A2 (pt) * 2005-09-12 2011-05-24 Speedel Pharma Ag piridilsulfonamidil-pirimidinas para a prevenção de falha de enxerto de vaso sangüìneo
KR20080111137A (ko) * 2006-04-13 2008-12-22 액테리온 파마슈티칼 리미티드 초기 단계 특발성 폐 섬유증을 위한 엔도텔린 수용체 대항제
EP1938812A1 (fr) * 2006-12-22 2008-07-02 Speedel Pharma AG Composition pharmaceutique utilisant aliskiren et avosentan
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (ko) 2017-06-23 2019-01-11 한국과학기술연구원 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
EP4448511A1 (fr) 2021-12-17 2024-10-23 Idorsia Pharmaceuticals Ltd Sel disodique de clazosentan, sa préparation et compositions pharmaceutiques le comprenant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
CA2162630C (fr) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
TW313568B (fr) * 1994-12-20 1997-08-21 Hoffmann La Roche
ES2221696T3 (es) 1997-08-19 2005-01-01 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de piridinas 2,5.disustituidas.
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Also Published As

Publication number Publication date
PL351794A1 (en) 2003-06-16
DE60033280T2 (de) 2007-11-22
HK1044943A1 (fr) 2002-11-08
HUP0200080A3 (en) 2003-01-28
JP2002538156A (ja) 2002-11-12
EP1185525A1 (fr) 2002-03-13
US20020137933A1 (en) 2002-09-26
ATE353325T1 (de) 2007-02-15
US6417360B1 (en) 2002-07-09
DK1185525T3 (da) 2007-06-04
TR200102562T2 (tr) 2002-02-21
KR20010102480A (ko) 2001-11-15
MA26776A1 (fr) 2004-12-20
RU2201928C1 (ru) 2003-04-10
KR100478798B1 (ko) 2005-03-24
CA2364906A1 (fr) 2000-09-08
DE60033280D1 (de) 2007-03-22
HRP20010630A2 (en) 2002-08-31
NZ513671A (en) 2003-04-29
AR044720A1 (es) 2005-10-05
ZA200107157B (en) 2002-11-29
WO2000052007A1 (fr) 2000-09-08
PT1185525E (pt) 2007-05-31
NO20014224L (no) 2001-08-31
AU756738B2 (en) 2003-01-23
YU62801A (sh) 2004-07-15
RU2001126348A (ru) 2004-03-20
CY1108002T1 (el) 2013-09-04
BR0008717A (pt) 2001-12-26
NO20014224D0 (no) 2001-08-31
NO320809B1 (no) 2006-01-30
HUP0200080A2 (en) 2002-06-29
JP3488203B2 (ja) 2004-01-19
CZ300324B6 (cs) 2009-04-22
RS50109B (sr) 2009-03-25
HRP20010630B1 (en) 2010-08-31
HK1044943B (zh) 2013-03-22
CA2364906C (fr) 2006-01-10
EP1185525B1 (fr) 2007-02-07
CZ20013108A3 (cs) 2002-02-13
AU3161100A (en) 2000-09-21
US6521631B2 (en) 2003-02-18
ES2280198T3 (es) 2007-09-16
ID30484A (id) 2001-12-13
CN1342158A (zh) 2002-03-27
PL198815B1 (pl) 2008-07-31
CN1342158B (zh) 2012-06-06

Similar Documents

Publication Publication Date Title
HUP0301654A3 (en) Novel n-pyrimidinyl-sulfamides, their use as endothelin receptor antagonists and pharmaceutical compositions containing them
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
IL144055A0 (en) 4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL144851A0 (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
EP1254116A4 (fr) Antagonistes du recepteur de l'integrine alpha v
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
EP1252162A4 (fr) Antagonistes du recepteur de l'integrine alpha v
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
AU2001290772A1 (en) Alpha v integrin receptor antagonists
PL351794A1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
AU9259801A (en) Alpha v integrin receptor antagonists
HUP0204113A3 (en) Novel integrin receptor antagonists, pharmaceutical compositions containing them and their use
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
AU5861900A (en) Receptor agonists and antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
HUP0202710A3 (en) Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use
HK1049151A1 (zh) 四氫化苯並吲衍生物、其製備方法和用作5-ht7受體拮抗劑的用途
EP1169042A4 (fr) Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
AU9088401A (en) Alpha v integrin receptor antagonists
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees